What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?

European Urology

Volumn 37, Issue 4, 2000, Pages 470-477

  Zlotta, Alexandre R ^a   Van Vooren, J P ^a   Huygen, K ^b   Drowart, A ^a   Decock, M ^a   Pirson, M ^a   Jurion, F ^b   Palfliet, K ^b   Denis, O ^b   Simon, J ^a   Schulman, C C ^a  

^a ERASME HOSPITAL   (Belgium)

^b PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

BCG; Bladder neoplasm; Immunotherapy; Maintenance therapy; Mycobacteria

Indexed keywords

BCG VACCINE; CYTOKINE; MYCOBACTERIUM ANTIGEN; TUBERCULIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

EID: 0034016219     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020170     Document Type: Article

References (27)